Eikon Therapeutics, Inc.
EIKN
$8.77
-$0.21-2.34%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -2.50% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 5.27% | ||||
| Operating Income | -5.27% | ||||
| Income Before Tax | -4.15% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -4.15% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -4.15% | ||||
| EBIT | -5.27% | ||||
| EBITDA | -5.87% | ||||
| EPS Basic | 90.67% | ||||
| Normalized Basic EPS | 90.64% | ||||
| EPS Diluted | 90.67% | ||||
| Normalized Diluted EPS | 90.64% | ||||
| Average Basic Shares Outstanding | 1,015.95% | ||||
| Average Diluted Shares Outstanding | 1,015.95% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||